本文選題：β-連環(huán)蛋白 + 膀胱癌�。� 參考：《蘭州大學(xué)》2017年碩士論文

【摘要】：目的:分析β-連環(huán)蛋白(β-catenin)在膀胱癌中異常表達(dá)情況,系統(tǒng)評價(jià)其異常表達(dá)與膀胱癌患者之間的臨床、病理學(xué)特征或疾病預(yù)后的相關(guān)性,探討β-catenin是否能夠成為治療膀胱癌的有效藥理學(xué)靶點(diǎn)。方法:對“主題詞+自由詞”在中國CNKI文獻(xiàn)總庫6.0版本(1996年～2016年9月12日)、維普科技類期刊庫6.5 (1989年～2016年9月12日)、中文生物醫(yī)學(xué)類電子庫(CBM) (1978年～2016年9月12日)、萬方數(shù)據(jù)(會議、期刊、論文等)平臺(1988年～2016年9月12日)、CDSR (Cochrane系統(tǒng)評價(jià)電子庫)(2016年1期)、EMBase (1974年～2016年9月12日)、PubMed/Medline (1975年～2016年9月12日)及谷歌學(xué)術(shù)網(wǎng)頁行網(wǎng)上查找,并翻閱期刊出版物行手工搜找,截止到2016年09月12日。遵照MOOSE (2000版)規(guī)范完成系統(tǒng)評價(jià)流程,對所納入各個(gè)CCS (病例-對照研究)的一般信息行定性總結(jié)、分析,用Revman manager (5.3版本)工具行數(shù)據(jù)定量分析。用OR值、HR值、95% CI值等來評估結(jié)果,用Chi2檢驗(yàn)、其P值來異質(zhì)性結(jié)果,用Z檢驗(yàn)、其P值評估偏倚。結(jié)果:最終歸入13個(gè)研究記錄,內(nèi)容為CCS記錄,包括了 862例膀胱癌患者,76例正常膀胱粘膜人群,含8篇英文文獻(xiàn),5篇中文文獻(xiàn)。Meta分析結(jié)果如下述:(1)膀胱癌組中的β-catenin表達(dá)水平高于正常膀胱粘膜組(95%CI =(7.61-50.48) ; OR= 19.60; P 0.00001),差異有統(tǒng)計(jì)學(xué)意義。(2)肌層浸潤性膀胱癌組中的β-catenin表達(dá)水平高于淺表性膀胱癌組(95%CI =(3.68-7.30);OR = 5.18; P 0.00001),差異有統(tǒng)計(jì)學(xué)意義。(3)高級別胱癌組中的β-catenin表達(dá)水平高于低級別膀胱癌組(95%CI= (2.89-5.71); OR = 4.06; P 0.00001),差異有統(tǒng)計(jì)學(xué)意義。(4) β-catenin表達(dá)與性別無顯著相關(guān)(95%CI = (0.57, 1.96);OR = 1.06; P = 0.85),差異沒有統(tǒng)計(jì)學(xué)意義。(5) β-catenin表達(dá)水平與腫瘤數(shù)目(多/單發(fā))無顯著性相關(guān)(95%CI= (0.36,1.88) ; OR = 0.82; P = 0.63),差異沒有統(tǒng)計(jì)學(xué)意義。(6) β-catenin表達(dá)水平和膀胱癌無進(jìn)展生存期(PFS)相關(guān)(95%CI= (1.22,6.14) ; HR = 2.74; P = 0.01),差異有統(tǒng)計(jì)學(xué)意義。結(jié)論:本論文Meta分析結(jié)果闡明,膀胱癌組β-連環(huán)蛋白表達(dá)水平高于正常膀胱粘膜組,即β-連環(huán)蛋白的高表達(dá)可能與膀胱癌發(fā)生有關(guān)。伴隨著β-連環(huán)蛋白表達(dá)水平升高,膀胱癌有一個(gè)更高TNM分期和病理級別,PFS越短,但與其膀胱癌腫瘤數(shù)目、性別則無顯著性相關(guān)。以上分析提示β-連環(huán)蛋白有可能預(yù)測出存在的初期癌變,或成為膀胱癌診斷的生物標(biāo)志物。
[Abstract]:Objective: to analyze the abnormal expression of 尾 -catenin in bladder cancer, and to evaluate systematically the relationship between the abnormal expression and the clinical, pathological features or prognosis of bladder cancer. To investigate whether 尾-catenin can be an effective pharmacological target in the treatment of bladder cancer. Methods: the "subject word free words" in the Chinese CNKI literature library 6.0 version (1996 ~ 12 September 2016), Weip Science and Technology Journal Library 6.5 (1989 ~ 2016 12 September, Chinese Biomedical Electronic Library CBM) (1978 ~ 12 September 2016) Universal data Journals, papers, etc.) platform (1988-12 September 2016 / CDSR / Cochrane systematic Review Electronic Library (2016-1) / EMBase (1974-Sept. 12, 2016) and Google academic Web site search, and manual search of journal publications, As of September 12, 2016. According to the MOOSE / 2000 version), the system evaluation process was completed. The general information of each CCS (case-control study) was qualitatively summarized and analyzed, and the quantitative analysis of the data was carried out with the Revman manager version 5.3. The results were evaluated with OR value and HR value of 95% CI, with Chi2 test, P value as heterogeneity result, and with Z test with P value to evaluate bias. Results: the CCS records were included in 13 study records, including 862 bladder cancer patients and 76 normal bladder mucosa patients. The expression of 尾 -catenin in bladder cancer group was higher than that in normal bladder mucosa group (7.61-50.48); OR = 19.60; P 0.00001, the difference was statistically significant. The expression level of 尾 -catenin in the high grade cystadenocarcinoma group was higher than that in the low grade bladder cancer group (2.89-5.71; OR = 4.06; P 0.00001, P 0.00001). The expression level of 尾 -catenin in the high grade cystadenocarcinoma group was higher than that in the lower grade bladder cancer group (2.89-5.71; OR = 4.06; P 0.00001, the difference was statistically significant) 尾 -catenin expression and 尾 -catenin expression in the high grade cystadenocarcinoma group were higher than those in the lower grade bladder cancer group. There was no significant correlation between sex (95 CI = 0.57, 1.96 or = 1.06; P = 0.85, P = 0.85). There was no significant correlation between 尾 -catenin expression level and the number of tumors (multiple / single). There was no significant correlation between 95 CI = 0.36% 1.88); OR = 0.82; P = 0.63N, there was no significant difference between 尾 -catenin expression and tumor number (multiple / single); OR = 0.82; P = 0.63N, there was no significant difference in 尾 -catenin expression. The level of PFS was significantly correlated with PFS), HR = 2.74 and P = 0.01, respectively. Conclusion: the results of Meta-analysis indicate that the expression of 尾 -catenin in bladder cancer is higher than that in normal bladder mucosa, that is, the high expression of 尾 -catenin may be related to the occurrence of bladder cancer. With the increase of 尾 -catenin expression, the higher TNM stage and pathological grade of bladder cancer were, the shorter the PFS was, but there was no significant correlation between the number of bladder cancer tumors and the sex. These results suggest that 尾-catenin may be a biomarker for the diagnosis of bladder cancer.
【學(xué)位授予單位】：蘭州大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2017
【分類號】：R737.14

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 高娟;董兵衛(wèi);張渭波;康煒;;膀胱癌中整合素連接激酶及相關(guān)信號轉(zhuǎn)導(dǎo)通路分子的表達(dá)及意義[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;2014年08期

2 李云飛;劉海濤;都興華;賴彩永;蘇澤軒;高雙全;;EN2與β-catenin在膀胱尿路上皮癌中的表達(dá)及其意義[J];南方醫(yī)科大學(xué)學(xué)報(bào);2013年09期

3 溫登瑰;張思維;鄭榮壽;楊漪;溫小多;單保恩;陳萬青;;中國2009年膀胱癌發(fā)病和死亡資料分析[J];中國腫瘤;2013年07期

4 李樂山;王化修;;膀胱移行細(xì)胞癌組織MVD和β-連環(huán)素蛋白的表達(dá)[J];中國熱帶醫(yī)學(xué);2009年09期

5 代新年;楊豐;紀(jì)祥瑞;;E-cad、β-cat和Ki-67在膀胱癌的表達(dá)及意義[J];實(shí)用醫(yī)藥雜志;2008年08期

6 劉利維,韓瑞發(fā),胥楓林;E-cadherin/catenin復(fù)合體在膀胱移行細(xì)胞癌中的表達(dá)及意義[J];天津醫(yī)科大學(xué)學(xué)報(bào);2005年03期

7 王毅,李澤良,孔垂?jié)?溫強(qiáng);β-catenin和E-cadherin蛋白在膀胱移行細(xì)胞癌中表達(dá)的臨床意義[J];中國醫(yī)科大學(xué)學(xué)報(bào);2004年03期

，

本文編號：2007600